Sutro Biopharma (NASDAQ:STRO) Director Buys $40,000.00 in Stock

Sutro Biopharma, Inc. (NASDAQ:STRO) Director Connie Matsui purchased 50,000 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were acquired at an average cost of $0.80 per share, with a total value of $40,000.00. Following the acquisition, the director directly owned 50,000 shares in the company, valued at approximately $40,000. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Sutro Biopharma Price Performance

Shares of Sutro Biopharma stock opened at $1.01 on Friday. The business has a fifty day simple moving average of $0.88 and a two-hundred day simple moving average of $0.84. Sutro Biopharma, Inc. has a 1 year low of $0.52 and a 1 year high of $4.60. The company has a market capitalization of $85.62 million, a price-to-earnings ratio of -0.40 and a beta of 1.61.

Sutro Biopharma (NASDAQ:STRO) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.25. Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 201.32%.The business had revenue of $63.74 million during the quarter, compared to the consensus estimate of $14.55 million. As a group, equities analysts anticipate that Sutro Biopharma, Inc. will post -2.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Wells Fargo & Company cut their price target on Sutro Biopharma from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday, August 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sutro Biopharma in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Sutro Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $4.47.

Institutional Trading of Sutro Biopharma

Institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC boosted its holdings in Sutro Biopharma by 78.9% in the 1st quarter. Acadian Asset Management LLC now owns 3,134,586 shares of the company’s stock valued at $2,037,000 after purchasing an additional 1,382,661 shares during the period. Nuveen LLC acquired a new position in Sutro Biopharma in the first quarter valued at about $189,000. Vontobel Holding Ltd. raised its stake in Sutro Biopharma by 100.0% in the first quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company’s stock valued at $33,000 after purchasing an additional 25,000 shares in the last quarter. RA Capital Management L.P. acquired a new position in Sutro Biopharma in the first quarter valued at about $2,885,000. Finally, Velan Capital Investment Management LP raised its stake in Sutro Biopharma by 3,333.3% in the first quarter. Velan Capital Investment Management LP now owns 1,030,000 shares of the company’s stock valued at $670,000 after purchasing an additional 1,000,000 shares in the last quarter. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.